CY1114163T1 - Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση - Google Patents

Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση

Info

Publication number
CY1114163T1
CY1114163T1 CY20131100624T CY131100624T CY1114163T1 CY 1114163 T1 CY1114163 T1 CY 1114163T1 CY 20131100624 T CY20131100624 T CY 20131100624T CY 131100624 T CY131100624 T CY 131100624T CY 1114163 T1 CY1114163 T1 CY 1114163T1
Authority
CY
Cyprus
Prior art keywords
methods
agents
cyclotheric
angiopycin
competitors
Prior art date
Application number
CY20131100624T
Other languages
English (en)
Inventor
Yongge Liu
Junichi Kambayashi
Original Assignee
Otsuka Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd filed Critical Otsuka Pharmaceutical Co., Ltd
Publication of CY1114163T1 publication Critical patent/CY1114163T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε μεθόδους μείωσης της καρδιοτοξικότητας ή/και βελτίωσης επιβίωσης από θεραπεία με παράγοντες ανθρακυκλίνης που περιλαμβάνει χορήγηση θεραπευτικώς αποτελεσματικής ποσότητας μιας σύνθεσης που περιλαμβάνει ένωση ανταγωνιστή αγγειοπιεσίνης ή φαρμακευτικώς αποδεκτό άλας αυτής ως δραστικό συστατικό, που χορηγείται ταυτοχρόνως προς τη χορήγηση ανθρακυκλίνης ή πριν από τη χορήγηση ανθρακυκλίνης.
CY20131100624T 2007-05-15 2013-07-23 Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση CY1114163T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93808907P 2007-05-15 2007-05-15
EP08755284.0A EP2146721B1 (en) 2007-05-15 2008-05-12 Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival

Publications (1)

Publication Number Publication Date
CY1114163T1 true CY1114163T1 (el) 2016-08-31

Family

ID=40122254

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100624T CY1114163T1 (el) 2007-05-15 2013-07-23 Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση

Country Status (25)

Country Link
US (1) US8372830B2 (el)
EP (1) EP2146721B1 (el)
KR (1) KR101508797B1 (el)
CN (2) CN103550233A (el)
AR (1) AR066544A1 (el)
AU (1) AU2008254273B2 (el)
BR (1) BRPI0811134A2 (el)
CA (1) CA2685186A1 (el)
CO (1) CO6280574A2 (el)
CY (1) CY1114163T1 (el)
DK (1) DK2146721T3 (el)
ES (1) ES2421639T3 (el)
HK (2) HK1138772A1 (el)
HR (1) HRP20130920T1 (el)
IL (1) IL202094A (el)
MX (1) MX2009012164A (el)
MY (1) MY150682A (el)
NZ (1) NZ581126A (el)
PL (1) PL2146721T3 (el)
PT (1) PT2146721E (el)
RU (1) RU2470643C2 (el)
SI (1) SI2146721T1 (el)
TW (1) TWI428131B (el)
UA (1) UA99914C2 (el)
WO (1) WO2008144269A2 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503085A (ja) * 2007-11-07 2011-01-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アンギオテンシン変換酵素阻害剤及びバソプレッシン受容体拮抗薬を含む複合治療
WO2013176955A1 (en) * 2012-05-21 2013-11-28 The General Hospital Corporation Cardioprotective compounds, their use with chemotherapy, and methods for identifying them
US20150238502A1 (en) * 2012-10-18 2015-08-27 University Of South Florida Compositions and Methods for Treating Stroke
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
US10172911B2 (en) 2013-10-01 2019-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
EP3400237A4 (en) 2016-01-04 2020-03-04 Adepthera LLC PEPTIDE ANALOGS
EP3416676B1 (en) 2016-02-09 2021-12-08 Adepthera LLC Dosing and use of long-acting clr/ramp agonists
US11110098B2 (en) * 2017-06-07 2021-09-07 University Of Kansas Methods and medicaments for the treatment of renal cell carcinoma
US20190153059A1 (en) 2017-06-30 2019-05-23 Adepthera Llc Peptide analogs
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574455A (en) * 1897-01-05 Switch-lock
US5744455A (en) * 1988-01-27 1998-04-28 New York University Reduction of anthracycline-induced cardiotoxicity
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Also Published As

Publication number Publication date
WO2008144269A3 (en) 2010-01-21
EP2146721A2 (en) 2010-01-27
IL202094A (en) 2015-06-30
BRPI0811134A2 (pt) 2014-09-30
EP2146721B1 (en) 2013-07-10
AU2008254273A1 (en) 2008-11-27
EP2146721A4 (en) 2010-08-25
KR101508797B1 (ko) 2015-04-06
AU2008254273B2 (en) 2013-03-28
WO2008144269A2 (en) 2008-11-27
HRP20130920T1 (hr) 2013-11-08
IL202094A0 (en) 2010-06-16
RU2009146376A (ru) 2011-06-20
CA2685186A1 (en) 2008-11-27
RU2470643C2 (ru) 2012-12-27
MX2009012164A (es) 2009-12-09
CO6280574A2 (es) 2011-05-20
SI2146721T1 (sl) 2013-10-30
CN101808517A (zh) 2010-08-18
NZ581126A (en) 2012-04-27
TW200916104A (en) 2009-04-16
HK1138772A1 (en) 2010-09-03
TWI428131B (zh) 2014-03-01
US8372830B2 (en) 2013-02-12
UA99914C2 (ru) 2012-10-25
US20100249104A1 (en) 2010-09-30
KR20100019439A (ko) 2010-02-18
HK1176318A1 (en) 2013-07-26
CN103550233A (zh) 2014-02-05
ES2421639T3 (es) 2013-09-04
DK2146721T3 (da) 2013-07-22
PT2146721E (pt) 2013-07-18
MY150682A (en) 2014-02-28
AR066544A1 (es) 2009-08-26
PL2146721T3 (pl) 2013-12-31

Similar Documents

Publication Publication Date Title
CY1114163T1 (el) Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση
CY1121853T1 (el) Συνδυαστικη θεραπεια για την αγωγη του διαβητη
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
EA201690033A3 (ru) Морфинановые соединения
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
CY1110013T1 (el) Συνδυασμοι για θεραπεια πολλαπλου μυελωματος
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
MX2009011900A (es) Curacion de herida diabetica.
AR062393A1 (es) Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
ECSP088237A (es) Derivados de quinolina y uso como agentes antitumor
EA202190247A1 (ru) ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
CY1115013T1 (el) Διαμορφωτες υποδοχεα 7 που προσομοιαζει toll